Abstract 3042
Background
KS is an HHV8 related lympho-angioproliferative disease with 4 clinical settings: post-transplant, epidemic, endemic, and classic. Although several studies described the clinical course of epidemic and post-transplant KS, the lack of large cohorts of C/E KS precluded such characterization. Our study aimed to describe the clinical course of C/E KS and identify risk factors for systemic treatment (ST) initiation and response.
Methods
We performed a retrospective study including 160C/E KS (n = 131 C and n = 29 E) patients diagnosed between 1990 and 2013 in 1 French dermato-oncology center).
Results
Median age was 62.6years [IQR:54.5;72.4] and Male/Female sex ratio was 140/20. During a median follow-up of 4.8years, 14% patients did not require any treatment while 44 and 41% required local and systemic treatments respectively. Among the 66 patients who required ST, 53% had more than one line of treatment. Cumulative incidence of ST initiation after 2years of follow-up was 28.4% [95%CI:20.5.35.5], and the median time from diagnosis to ST initiation was 8.8years [95%CI:4.7;12.7]. Instantaneous risk of ST initiation decreases over time. Multivariate analysis identified 3 risk factors for ST initiation: E versus C KS (HR: 4.19 [95%CI:2.32; 7.55]), total number of lesions higher than 10 (HR: 4.68 [95%CI:2.47;8.87]), and presence of edema (HR: 1.84 [95%CI:1.02;3.33]). Best overall response (BOR) after the first-line of treatment was CR in 14%, PR in 69%, SD in 8% and PD in 9% patients. Type of first-line therapy (low dose interferon, chemotherapy or other), type of KS (E or C), age at therapy initiation and time between diagnosis and ST initiation were not associated with BOR. Given the chronic evolution of KS and the impact of ST on the quality of life, we evaluated the treatment-free interval (TFI=time between end of first-line and start of second-line) during the first 2years after ST initiation. The mean TFI was 306days [95%CI:199;413] for interferon and 422days [95%CI:320;524] for chemotherapy treated patients.
Conclusions
Our study reveals important ST initiation risk factors in C/E KS. No major efficacy difference was observed between interferon and chemotherapy, thus enabling treatment choice based on patient’s fitness.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract